

Tislelizumab

Cat. No.:	HY-P99052
CAS No.:	1858168-59-8
Target:	PD-1/PD-L1
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma ^{[1][2][3]} .								
In Vivo	<p>Tislelizumab (10 mg/kg; Intraperitoneal injection; Once a week; 4 weeks) has significant antitumor effect in the B16F10 melanoma mouse model^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table><tr><td>Animal Model:</td><td>B16F10/GM-CSF tumor cells treated hPD-1 C57BL/6 transgenic mice^[2]</td></tr><tr><td>Dosage:</td><td>10 mg/kg</td></tr><tr><td>Administration:</td><td>Intraperitoneal injection (i.p.); once a week for 4 weeks.</td></tr><tr><td>Result:</td><td>Exerted remarkable antitumor efficacy, resulting in approximate 86.7% tumor growth inhibition.</td></tr></table>	Animal Model:	B16F10/GM-CSF tumor cells treated hPD-1 C57BL/6 transgenic mice ^[2]	Dosage:	10 mg/kg	Administration:	Intraperitoneal injection (i.p.); once a week for 4 weeks.	Result:	Exerted remarkable antitumor efficacy, resulting in approximate 86.7% tumor growth inhibition.
Animal Model:	B16F10/GM-CSF tumor cells treated hPD-1 C57BL/6 transgenic mice ^[2]								
Dosage:	10 mg/kg								
Administration:	Intraperitoneal injection (i.p.); once a week for 4 weeks.								
Result:	Exerted remarkable antitumor efficacy, resulting in approximate 86.7% tumor growth inhibition.								

CUSTOMER VALIDATION

- J Pharm Anal. 2024 Apr 25:100984.
- Cancer Cell Int. 2024 Jun 29;24(1):225.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Jie Wang, et al. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 May 1;7(5):709-717.

[2]. Hong Y, et al. Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage. FEBS Open Bio. 2021 Mar;11(3):782-792.

[3]. Zhu K, et al. Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients. Front Pharmacol. 2024 Feb 22;15:1355081.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA